InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,617.63
(
0.04%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.86
(
-0.01%
)
Bitcoin
62,566.30
(
0.37%
)
Post# of 648882
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dDT

Send PM Follow Ignore
Followers 470
Posts 76416
Boards Moderated 3
Alias Born 03/31/2008

dDT

Re: None

Monday, 01/26/2015 7:18:04 AM

Monday, January 26, 2015 7:18:04 AM

Post# of 648882
Gilead adds investigational NS5A inhibitor to generic licensing agreements

Gilead Sciences (NASDAQ:GILD) updates its generic licensing agreements with its India-based partners to include the investigational NS5A inhibitor GS-5816, currently in Phase 3 development as part of a single tablet regimen with sofosbuvir for the treatment of all six genotypes of hepatitis C. Once approved, the eight firms will be able to manufacture GS-5816/sofosbuvir and distribute it in 91 developing countries.
If approved, it will be the first single tablet pan-genotypic all-oral HCV treatment.
The companies involved are Biocon Ltd., Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up